Filipe Frazao / Shutterstock.com
February’s amendments to the Australian IP Act seek to increase the effectiveness and efficiency of the country’s IP system. LSIPR takes a look at the major changes and considers who will benefit most in the life sciences sector.
Just two years after one of the biggest ever shake-ups to Australian patent law—the Raising the Bar Act of 2012—further change is in store for pharmaceutical and biotechnology companies operating in Australasia.
On February 9 this year, the Australian parliament passed into law the Intellectual Property Laws Amendment Bill 2014. The act received Royal Assent on February 25.
The act makes five major amendments, four of which will affect life sciences businesses based in Australia.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Australia, IP, TRIPS, Federal Court of Australia, JSCOT, patent, patent protection,
